Bernhardt Zeiher Biography and Net Worth

Bernhardt G. Zeiher, M.D., FACP, FCCP, began serving as director of Amylyx in 2024. Dr. Zeiher has more than 20 years of experience in the pharmaceutical industry with expertise in drug development. He is a member of the Board of Directors at Entrada Therapeutics and most recently served as Chief Medical Officer (CMO) of Astellas Pharma from 2018 to 2022. As CMO, Dr. Zeiher led the development of early and late-stage therapies, medical and regulatory affairs, pharmacovigilance, and quality assurance for an organization of nearly 3,000 global employees. His time overseeing Astellas’ development sector was the most productive period in the company’s history, with approvals for Cresemba^®, Xtandi^®, Xospata^®, Padcev^® and Evrenzo^®, as well as the acquisition submission of VEOZAHTM (fezolinetant), which was approved by the FDA in May 2023. Prior to his time at Astellas, Dr. Zeiher held various roles leading drug development at other pharmaceutical companies including Pfizer, Eli Lilly and Company, and Merck, and he also practiced medicine at a tertiary medical center in Indianapolis upon completing his physician training. 

Dr. Zeiher, fellow of the American College of Physicians and the American College of Chest Physicians, received a B.S. in Biology from the University of Toledo and an M.D. from Case Western Reserve University School of Medicine. He also completed his internal medicine residency and chief residency at the University Hospitals of Cleveland and did a fellowship in Pulmonary and Critical Care Medicine at the University of Iowa Hospitals and Clinics.